Infinity Pharmaceuticals Inc. (NASDAQ: INFI) is having an overwhelmingly strong start to the trading session this morning after the company announced that a presentation surrounding IPI-549 is coming. Of course, the coming clinical data caused excitement among investors, leading to gains in the stock and prompting an alert from our partners at Trade Ideas. Currently (10:39), INFI is trading at $2.72 per share after a gain of $1.05 per share (63.02%) thus far today.
INFI Announces Coming Presentation
As mentioned above, Infinity Pharmaceuticals is having a strong time in the market today after the company announced an abstract presentation that describes new data surrounding IPI-549. IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gama, also known as PI3K-gamma.
In a press release, INFI said that the treatment has been selected as a late-breaking presentation during the oral session at the 2017 Society for Immunotherapy of Cancer Annual Meeting. The meeting will take place in National Harbor, MD on November 10th through 12th. Also, a clinical-trials-in-progress presentation will be given. This presentation will surround the Phase 1/1b clinical study which is currently ongoing and designed to explore the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo®.
More Details On The IPI-549 Phase 1 Clinical Trial
IPI-549 has shown in preclinical trials to reprogram macrophages from a pro-tumor (M2) to an anti-tumor (M1) phenotype and is able to overcome resistance to checkpoint inhibition as well as enhance the activity of checkpoint inhibitors. INFI believes that the treatment may have potential to treat a broad range of solid tumors and represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies like checkpoint inhibitors.
The current Phase 1 clinical trial is ongoing and designed to assess the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of the treatment as a monotherapy as well as in combination with Opdivo. During the clinical trial, INFI will treat approximately 200 patients with advanced solid tumors. The clinical study surrounding IPI-549 is a four-part study. During the study, the treatment will be tested as a monotherapy and combination therapy in dose-escalation components. The treatment is also going to be assessed in monotherapy expansion components as well as combination therapy expansion components.
On the combination expansion side, multiple cohorts that have been designed to evaluate IPI-549 in patients with specific types of cancers, including non-small cell lung cancer, melanoma, and head and neck squamous cell carcinoma whose tumors show initial resistance or subsequently develop resistance to immune checkpoint therapy will be tested. The combination expansion will also include a cohort of patients with triple negative breast cancer who have not been previously exposed to immune checkpoint blockade therapy.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on INFI. In particular, we’ll continue following the story surrounding IPI-549, and we are excited to learn more from the data offered in the presentations mentioned above. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!